Introduction -- Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia/Lymphoma -- Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies -- Monitoring AML Response Using “Difference From Normal” Flow Cytometry -- ML-DS: A Unique Condition for Measurable Residual Disease Detection -- Advancements in Next Generation Sequencing for Detecting Minimal Residual Disease.

This volume provides a concise yet comprehensive overview of minimal residual disease (MRD) testing. The text reviews the history of MRD testing, MRD testing for acute lymphoblastic leukemia/lymphoma, molecular diagnostics for MRD analysis in hematopoietic malignancies, the use of "difference from normal" flow cytometry in monitoring AML response, ML-DS for measurable residual disease detection, and advancements in next generation sequencing for detecting MRD. Written by experts in the field, Minimal Residual Disease Testing: Current Innovations and Future Directions is a valuable resource for hematologists, oncologists, pathologists, and radiologists on the variety of technologies available to detect MRD and how best to integrate these platforms into clinical practice.